Mycobacterium szulgai: Difference between revisions
Jump to navigation
Jump to search
Gerald Chi- (talk | contribs) mNo edit summary |
Gerald Chi- (talk | contribs) m (→Treatment) |
||
| Line 17: | Line 17: | ||
==Treatment== | ==Treatment== | ||
===Antimicrobial regimen=== | ===Antimicrobial regimen=== | ||
* in vitro susceptibility<ref>{{Cite journal| doi = 10.1164/rccm.200604-571ST| issn = 1073-449X| volume = 175| issue = 4| pages = 367–416| last1 = Griffith| first1 = David E.| last2 = Aksamit| first2 = Timothy| last3 = Brown-Elliott| first3 = Barbara A.| last4 = Catanzaro| first4 = Antonino| last5 = Daley| first5 = Charles| last6 = Gordin| first6 = Fred| last7 = Holland| first7 = Steven M.| last8 = Horsburgh| first8 = Robert| last9 = Huitt| first9 = Gwen| last10 = Iademarco| first10 = Michael F.| last11 = Iseman| first11 = Michael| last12 = Olivier| first12 = Kenneth| last13 = Ruoss| first13 = Stephen| last14 = von Reyn| first14 = C. Fordham| last15 = Wallace| first15 = Richard J.| last16 = Winthrop| first16 = Kevin| last17 = ATS Mycobacterial Diseases Subcommittee| last18 = American Thoracic Society| last19 = Infectious Disease Society of America| title = An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases| journal = American Journal of Respiratory and Critical Care Medicine| date = 2007-02-15| pmid = 17277290}}</ref> | * '''1. in vitro susceptibility'''<ref>{{Cite journal| doi = 10.1164/rccm.200604-571ST| issn = 1073-449X| volume = 175| issue = 4| pages = 367–416| last1 = Griffith| first1 = David E.| last2 = Aksamit| first2 = Timothy| last3 = Brown-Elliott| first3 = Barbara A.| last4 = Catanzaro| first4 = Antonino| last5 = Daley| first5 = Charles| last6 = Gordin| first6 = Fred| last7 = Holland| first7 = Steven M.| last8 = Horsburgh| first8 = Robert| last9 = Huitt| first9 = Gwen| last10 = Iademarco| first10 = Michael F.| last11 = Iseman| first11 = Michael| last12 = Olivier| first12 = Kenneth| last13 = Ruoss| first13 = Stephen| last14 = von Reyn| first14 = C. Fordham| last15 = Wallace| first15 = Richard J.| last16 = Winthrop| first16 = Kevin| last17 = ATS Mycobacterial Diseases Subcommittee| last18 = American Thoracic Society| last19 = Infectious Disease Society of America| title = An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases| journal = American Journal of Respiratory and Critical Care Medicine| date = 2007-02-15| pmid = 17277290}}</ref> | ||
:* M. szulgai is susceptible in vitro to most antituberculous drugs including [[Quinolones]] and newer [[Macrolides]] | :* M. szulgai is susceptible in vitro to most antituberculous drugs including [[Quinolones]] and newer [[Macrolides]]. | ||
* Pulmonary infection | * '''2. Pulmonary infection''' | ||
:* Preferred regimen: three- | :* Preferred regimen: three- or four-drug regimen that includes 12 months of negative sputum cultures while on therapy | ||
* Extrapulmonary infection | * '''3. Extrapulmonary infection''' | ||
:* Preferred regimen: combination antituberculous | :* Preferred regimen: combination antituberculous medications based on in vitro susceptibilities for 4 to 6 months | ||
==References== | ==References== | ||
Revision as of 16:54, 7 July 2015
| style="background:#Template:Taxobox colour;"|Mycobacterium | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| style="background:#Template:Taxobox colour;" | Scientific classification | ||||||||||||||
|
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Mycobacterium szulgai is a species of Mycobacterium. It is a Scotochromogen and is currently ungrouped. It is known to cause skin infections.[1]
Treatment
Antimicrobial regimen
- 1. in vitro susceptibility[2]
- M. szulgai is susceptible in vitro to most antituberculous drugs including Quinolones and newer Macrolides.
- 2. Pulmonary infection
- Preferred regimen: three- or four-drug regimen that includes 12 months of negative sputum cultures while on therapy
- 3. Extrapulmonary infection
- Preferred regimen: combination antituberculous medications based on in vitro susceptibilities for 4 to 6 months
References
- ↑ Hizawa K, Nagata Y, Kudo T, Taniguchi M, Matsumoto T, Iida M (September 2009). "[A case of steroid-dependent ulcerative colitis complicated by skin infection of Mycobacterium szulgai]". Nippon Shokakibyo Gakkai Zasshi (in Japanese). 106 (9): 1359–63. PMID 19734708.
- ↑ Griffith, David E.; Aksamit, Timothy; Brown-Elliott, Barbara A.; Catanzaro, Antonino; Daley, Charles; Gordin, Fred; Holland, Steven M.; Horsburgh, Robert; Huitt, Gwen; Iademarco, Michael F.; Iseman, Michael; Olivier, Kenneth; Ruoss, Stephen; von Reyn, C. Fordham; Wallace, Richard J.; Winthrop, Kevin; ATS Mycobacterial Diseases Subcommittee; American Thoracic Society; Infectious Disease Society of America (2007-02-15). "An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases". American Journal of Respiratory and Critical Care Medicine. 175 (4): 367–416. doi:10.1164/rccm.200604-571ST. ISSN 1073-449X. PMID 17277290.